iPSC Archives | BioInformant

I Peace Selected as a TOP 10 Awardee for the “Top 10 Longevity Breakthrough Awards 2026”

October 1, 2026 By BioInformant Team Leave a Comment

NEWS PROVIDED BY I Peace, Inc., Oct 1, 2026, 09:01 ET

PALO ALTO, Calif., Oct. 1, 2026 — I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPS cell) technologies for regenerative medicine and longevity, today announced that it was selected as one of the awardees for the Top 10 Longevity Breakthrough Awards at the 2026 Asia-Pacific Healthy Longevity International Summit. The award was presented for I Peace’s research and development of iPSF, a cell-free product derived from culture supernatant of iPS cells.

“We are honored to be recognized as one of this year’s Top 10 Longevity Breakthrough award recipients,” said Dr. Koji Tanabe, Founder and CEO of I Peace, Inc. “This recognition reflects our team’s commitment to advancing the possibilities of iPS cell technology and exploring new approaches in the longevity field. We are proud to be included among such respected innovators and look forward to continuing our efforts to progress iPSC science.” [Read more…]

Direct Cell Reprogramming: What Is It and How Does It Work?

September 1, 2026 By Cade Hildreth, Founder & President 8 Comments

Direct cell reprogramming is the in vitro (laboratory) or in vivo (in the body) reprogramming of somatic cells into other cell types without the need for an intermediate pluripotent state. Another term for direct cell reprogramming is transdifferentiation, which is the direct conversion of one differentiated cell type into another.

There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 7,149+ stem cell trials registered on ClinicalTrials.gov and stem cell publications have increased dramatically in recent years, recently surpassing 500,000+ on PubMed.gov.

However, for all their promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]

Induced Pluripotent Stem Cell (iPS Cell) Applications in 2026

August 1, 2026 By Cade Hildreth, Founder & President Leave a Comment

Since the discovery of induced pluripotent stem cell (iPSC) technology 20 years ago in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]

Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation

July 13, 2026 By BioInformant Team Leave a Comment

The companies will generate data using Applied StemCell’s induced pluripotent stem cell technologies and Syntax Bio’s Cellgorithm™ platform to support application discovery and development

CHICAGO & MILPITAS, Calif. — Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advance stem cell research and therapeutic application discovery and development. [Read more…]

RoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess Solutions

July 8, 2026 By BioInformant Team Leave a Comment

Partnership pairs Applied StemCell’s induced pluripotent stem cell technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems to accelerate development and manufacturing of advanced therapies

MILPITAS, Calif. and FREDERICK, Md., July 8, 2026 — Applied StemCell, Inc., a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions. The collaboration combines Applied StemCell’s GMP-compatible iPSC technology with RoosterBio’s engineered media systems and scalable manufacturing expertise to provide advanced therapy developers with a unique bioprocess solution supporting research through clinical manufacturing. [Read more…]